Wells Fargo & Co

Wells Fargo cuts equity targets on biotech, renewable, and consumer staples, signaling caution amid inflation, rising rates, and AI‑cyber‑risk concerns.

Wells Fargo’s recent institutional sell‑offs, aggressive analyst cuts and geopolitical risk hint at a fragile earnings outlook—what investors should know.

Wells Fargo’s March 2026 updates: a $200k FFA grant, new tech‑stock coverage, and the end of a 15‑year consent order—boosting reputation, research depth and regulatory freedom.

Wells Fargo’s $267 bn market cap, strong $2.1 tn asset base, and steady $84.57 stock price show solid stability, but fintech pressure and shifting analyst targets hint at risks and growth chances in 2026.

Wells Fargo cuts Autodesk’s target price to $365, citing potential earnings, valuation and market‑sentiment shifts that may reshape investors’ outlook.

Wells Fargo’s January 2026 trading shows modest net purchases amid large sell‑orders, while its research updates raise targets for tech, industrial and consumer stocks—highlighting disciplined, value‑focused upside potential.

Wells Fargo’s recent institutional trades show active buying by top wealth managers and a balanced liquidity profile amid renewed media buzz.

Wells Fargo’s new research push raises targets for Take‑Two, eBay and biotech, while trimming Guidewire, CoreWeave and D.R. Horton—how will this shift impact its own stock and investors?

Wells Fargo’s 2026 headcount cut, crypto‑policy lobbying, and volatile analyst ratings highlight a strategic pivot that could reshape risk and earnings.

Wells Fargo adjusts valuations: trims REIT targets, boosts outlook for Merck & Agilent, showing a balanced strategy for investors.